Evidence check: Pharmakogenetik Medicheck in the context of Wechseljahre

Evidence for pharmacogenetic testing (e.g., Medicheck) in menopause is currently **moderate to mixed**. Genetic variants in enzymes like CYP2D6, CYP2C19, or COMT may influence the metabolism of hormone replacement therapy (HRT) or antidepressants. However, large prospective trials demonstrating clinical utility are lacking. Most evidence comes from pharmacokinetic data and observational studies, not RCTs. Routine use is not standard of care. Testing may be considered in individual cases (e.g., unexpected side effects or poor response) but should not replace clinical judgment. Be cautious of marketing claims.